Tvardi Therapeutics
TVRD
179 hedge funds and large institutions have $318M invested in Tvardi Therapeutics in 2022 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 50 increasing their positions, 59 reducing their positions, and 26 closing their positions.
341% more call options, than puts
Call options by funds: $3.74M | Put options by funds: $847K
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
0.15% more ownership
Funds ownership: 1.65% → 1.8% (+0.15%)
2% less funds holding
Funds holding: 183 → 179 (-4)
15% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 59
18% less capital invested
Capital invested by funds: $387M → $318M (-$69.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$25.8M |
| 2 |
Millennium Management
New York
|
+$7.58M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$2.68M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.67M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$11.2M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.58M |
| 3 |
Renaissance Technologies
New York
|
-$1.93M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$1.93M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.62M |
TVRD Hedge Fund Activity: Q2 2022 in Review
179 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2022, worth a combined $318M — down 18% from $387M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new TVRD positions and 26 closed out — a net gain of 2 holders — while 50 added to existing stakes and 59 trimmed.
The largest buyer was Bain Capital Life Sciences Investors, opening a new position worth an estimated $25.8M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $11.2M sold.
- 179 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2022, down from 183 in Q1 2022.
- Funds reported $318M of Tvardi Therapeutics stock for Q2 2022, down 18% quarter-over-quarter.
- 28 funds opened new Tvardi Therapeutics positions in Q2 2022 and 26 closed out, a net change of +2 holders.
- The largest Tvardi Therapeutics buyer in Q2 2022 was Bain Capital Life Sciences Investors, an estimated $25.8M added.
- The largest Tvardi Therapeutics seller in Q2 2022 was Jacobs Levy Equity Management, an estimated $11.2M sold.
Based on aggregated 13F filings for Q2 2022.